SUMMARY Serial coagulation studies were obtained in 25 patients treated with intracoronary streptokinase infusion for myocardial infarction (23 patients) or coronary insufficiency (two patients) to determine the frequency of systemic fibrinolytic activity. Clotting studies were obtained before and after infusion and at 4-hour intervals until normalization. Intracoronary thrombolysis was successful in 20 of 23 patients (87%) with myocardial infarction. Streptokinase dosage in this study was 201,000 ± 74,000 IU (± SD). Systemic fibrinolytic activity, defined as > 70% reduction of fibrinogen using a functional assay (Claus method), occurred in 22 of 25 patients (88%) and was present at a mean streptokinase dosage of 119,000 + 52,000 IU. Fibrinogen in the total population decreased from 342 ± 80 to 87 ± 94 mg% (p < 0.0001). In patients with systemic effect, the mean fibrinogen level after infusion was 17% of baseline, increased to 43% at 24 hours, and returned to normal at 30 hours. Plasminogen decreased to 7% of baseline activity after infusion (p < 0.0001), was 44% of baseline at 24 hours, and returned to normal at 48 hours. Intraprocedural sampling during infusion showed reduction of fibrinogen by 25% after 30,000 IU (p < 0.0005) and by 71% at 120,000 IU (p < 0.0001); plasminogen decreased by 50% after 30,000 IU (p < 0.0001) and by 84% at 120,000 IU (p < 0.0001). Prothrombin time increased from 11.5 ± 0.8 seconds to 22.0 ± 7.8 seconds after infusion (p < 0.0001) and returned to normal at a mean of 18 ± 11 hours after infusion. Partial thromboplastin time was markedly prolonged (> 100 seconds) after infusion, returned to : 2 times control at 5 ± 2 hours, and returned to normal at 9 ± 4 hours after infusion. Fibrinogen degradation products were < 10 gg/ml before infusion, increased to > 40 gg/ml after infusion, and remained > 40 ,g/ ml in 40% of patients at 24 hours after infusion. 
INTRACORONARY streptokinase infusion achieves thrombolysis and reperfusion in a high percentage of patients with acute myocardial infarction, and beneficial effects with this therapy have been reported. '-8 Intracoronary infusion provides a higher local concentration of streptokinase at a lower total dosage compared with systemic infusion and potentially reduces the incidence of systemic fibrinolytic activity and the risk of major bleeding complications. However, the indirect mechanism of streptokinase activation of fi-brinolysis suggests that a significant incidence of systemic fibrinolytic activity may also occur with the lower streptokinase dosage levels currently used with intracoronary infusion. Although initial reports suggest that significant alterations in coagulation variables are infrequent,', 2 only limited information is available regarding fibrinolytic effects with this therapy. We therefore studied the incidence of systemic fibrinolytic activity and the extent and duration of alteration of coagulation variables during intracoronary streptokinase infusion in patients with acute myocardial infarction or acute coronary insufficiency.
Materials and Methods
Intracoronary streptokinase infusion was performed in 26 patients during the acute phase of transmural myocardial infarction (24 patients) or acute coronary insufficiency (two patients) between May 1980 and April 1982. Twenty-five of these 26 patients received a total intracoronary streptokinase dosage conforming to protocol specification for minimal dosage (D 80,000 IU) and underwent serial coagulation studies. These 25 patients form the basis of this report. The one patient not included had myocardial infarction, received only 30,000 IU of streptokinase before the procedure was stopped for technical and logistical reasons, and did not undergo serial coagulation studies. Criteria for transmural infarction required prolonged chest pain unrelieved by nitroglycerin and persistent ECG STsegment elevation with associated reciprocal depression. Diagnosis of infarction was subsequently confirmed by typical ECG evolutionary changes (Q waves) and positive creatine kinase (CK-MB) isoenzyme determinations. Diagnosis of coronary insufficiency was based on recurrent episodes of prolonged chest pain without diagnostic ECG or enzyme changes of infarction. Patients were required to have no contraindication to anticoagulation or thrombolytic therapy. All patients gave written, informed consent. The procedures for intracoronary streptokinase infusion at this institution have been reported in detail.' Right-and left-heart catheterization were performed using the femoral approach. Heparin, 5000-10,000 units, was given intravenously after arterial catheter insertion. An arterial sheath with sidearm (Cordis) was used for leftheart catheterization to allow continuous arterial pressure monitoring during intracoronary infusion. After baseline pressure recordings, left ventriculography and coronary angiography, streptokinase infusion was begun. Infusion was performed through a small (#2-3F size) subselective infusion catheter, which was advanced as near as possible to the site of occlusion. A 20,000-IU bolus of streptokinase was initially given, followed by infusion at 2000-5000 IU/min for 30-90 minutes. After patency was first restored, the infusion was usually continued for 30-45 minutes or until residual thrombus was no longer apparent by angiography and the increase in luminal diameter at the previous occlusion site appeared to be maximal. After completion of the infusion, repeat angiography was performed and patients were returned to the coronary care unit for observation and continued management. Arterial and venous sheaths were left in the catheterization site for [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] hours to provide local hemostasis if any major coagulation abnormality was present after infusion and were removed when coagulation studies had returned toward normal. Continuous i.v. heparin infusion was begun after the procedure when the activated partial thromboplastin time (PTT) had returned to -2 times control; heparin was infused at 800-1200 units/hour to maintain the PTT at 2-3 times control and was continued for 3-7 days.
Coagulation studies were obtained immediately before and after the procedure and every 4 hours until values had normalized. Subsequent coagulation studies were obtained as indicated to monitor anticoagulant therapy. Coagulation studies included fibrinogen, prothrombin time (PT), PTT, plasminogen, and fibrinogen degradation products (FDPs). Specimens were collected in tubes containing 3.8% sodium citrate. Fibrinogen was assayed with a fibrometer system using the modified thrombin time method of Claus (DATAFl, American Dade). Prothrombin time was performed using a one-stage method (Ortho Diagnostics) and activated PTT was determined using activated cephaloplastin reagent (Actin) on a Coagulizer System (Lancer). Plasminogen was determined by synthetic substrate assay using the Protopath fluorometric system (American Dade). FDPs were assayed using a semiquantitative rapid latex agglutination assay (Thrombo-Wellcotest, Wellcome).
In a subgroup of 15 patients, samples for fibrogen and plasminogen were obtained after each 30,000 IU of streptokinase to determine the streptokinase dosage levels at which significant changes developed. Samples were obtained from the venous catheter while the infusion was interrupted for repeat angiography to assess response at these intervals during the procedure.
Systemic fibrinolytic activity was defined as a major (> 70%) decrease of fibrinogen from baseline levels. Data are expressed as the mean SD. The paired t test was used to compare data within groups and analysis of variance to assess differences between groups.
Results
The study population consisted of 23 patients with acute transmural infarction and two patients with coronary insufficiency. The clinical profiles of these patients are shown in table 1 Abbreviations: LAD = left anterior descending coronary artery; LCx = left circumflex; RCA = right coronary artery; SK = streptokinase; + = present; -= absent; + / -= reocclusion during procedure. mg% (p < 0.0001, table 2). In patients with systemic effects, fibrinogen decreased from 333 ± 70 to 58 ± 21 mg% (p < 0.0001), representing a reduction to 17% of the baseline level. The mean streptokinase dose in these patients was 207,000 + 75,000 IU (range 80,000-400,000 IU). In the remaining three patients (12%), major reduction of fibrinogen did not occur. Fibrinogen in these patients decreased slightly from 390 + 75 mg% to 336 + 64 mg% (NS). The mean streptokinase dosage in patients without systemic effect was 160,000 + 62,000 IU (range 90,000-210,000 IU).
The mean streptokinase dosage at which systemic effect was documented (during intraprocedural sampling or the total dose in patients not having intraprocedural sampling) was 119,000 ± 52,000 IU (range 30,000-240,000 IU) (table 1). The changes in fibrinogen concentration in the subgroup of patients from whom samples were taken at 30,000-IU intervals during infusion are shown in table 3 . All patients with intraprocedural sampling had systemic fibrinolytic activity. Fibrinogen decreased progressively at each sampling interval during the course of infusion. Fibrinogen was reduced by 25% after the initial 30,000 IU (p < 0.0005) and by 43% after 60,000 IU (p < 0.0001). Fibrinogen was decreased by 71% after 120,000 IU and was 17% of the baseline level after 180,000 IU (p < 0.0001).
Serial changes in fibrinogen for the total group and in subgroups with and without systemic effects after completion of infusion are shown in The results of our current study expand these earlier observations on the frequency of systemic fibrinolysis and also characterize the extent and duration of alteration of coagulation variables after intracoronary streptokinase administration. These results indicate that systemic fibrinolytic activity (> 70% reduction of fibrinogen) occurred in 88% of patients with a mean streptokinase dosage of 201,000 + 15,000 IU. This mean dosage reflects an increase in total dosage during the study and includes our earlier reported experience.7
However, intraprocedural sampling was begun concurrent with the increase in total dosage to allow for assessment of dosage levels at which major changes in coagulation variables appeared. The results of intraprocedural sampling indicate that major reduction of fibrinogen was present at a mean dose of 120,000 IU and mean plasminogen activity was reduced by 80% at this dosage. For all patients with systemic fibrinolysis, the mean dosage at which major fibrinogen reduction was documented was 119,000 + 12,000 IU of streptokinase.
The mechanism of activation of the fibrinolytic system by streptokinase is indirect and involves a two-step process.'2 Streptokinase is an antigenic product of streptococci that may be neutralized if sufficient antistreptococcal antibodies are present or may react with plasminogen to form an activator complex that converts additional plasminogen to the active protease plasmin. Plasmin may in turn be inactivated by circulating inhibitors (antiplasmins), degrade fibrin thrombi to soluble fragments (thrombolysis), or degrade fibrinogen and other proteins (fibrinolysis). The dosage of streptokinase at which systemic fibrinolysis occurs is predominantly dependent on the level of antistreptococcal antibodies and endogenous plasmin inhibitors and can be estimated using the streptokinase resistance test. 12 Levels of antistreptokinase titers have been evaluated in different geographical regions and patient populations. 1'-" In these studies, antistreptokinase titers were 250,000 IU or less in 85-90% of adult populations, and 60-80% of subjects tested had streptokinase resistance titers of 100,000 IU or less. As a result of the indirect mechanism of streptokinase activation of fibrinolysis, doses only slightly in excess of the resistance titer should produce a systemic lytic state and may result in a phase of more intense hyperplasminemia than with higher dosage, because levels of activator that produce very high levels of plasmin are formed. 12 The degree of change in plasma fibrinogen concentration after intracoronary streptokinase appears to distribute in a bimodal pattern: minimal or no change in some patients and major change in others. Analysis of changes in group mean values may indirectly reflect the relative proportions of minimal and major alterations, but do not allow assessment of the frequency of either response. In the study reported by Rentrop et al. ,2 the group mean fibrinogen decreased from 451 + 93 to 413 ± 82 mg%, representing only an 8% overall reduction, which is similar to the magnitude of fibrinogen reduction in our small subgroup of patients without major change, but is considerably different from the overall fibrinogen reduction of 75% in our study. Reduto et al.5 reported mean fibrinogen reductions of 60% and 62% in subgroups of patients with and without successful reperfusion using total streptokinase dosages similar to those used by Rentrop et al. However, the frequency of major and minor alterations was not reported in either study.
The explanation for the difference in results encountered in our study, which demonstrate a high incidence North American patient populations, differences in techniques of intracoronary streptokinase administration, or to other factors. The Claus method of fibrinogen assay we used measures clottable protein and is influenced by high concentrations of heparin and FDPs; thus, it may be considered to represent a functional assay of fibrinogen. In contrast, chemical assays that use alkaline precipitation measure both clottable protein and FDPs and may give higher values for fibrinogen when FDPs are present. The use of subselective rather than ostial infusion in our study and the use of higher infusion rates may also be important factors influencing the inhibitory systems and producing a high incidence of systemic fibrinolysis. Nevertheless, the results of our study are consistent with available data on the ranges of streptokinase resistance levels in different populations and the mechanism of streptokinase activation of fibrinolysis, and indicate that a systemic fibrinolytic state with pronounced reduction of fibrinogen occurs in a high percentage of patients receiving short-course, "low-dose" intracoronary streptokinase infusion. The milder reductions of fibrinogen and appearance of fibrinogen degradation products in the remaining patients are consistent with enhanced fibrinolytic activity of a milder degree.
The magnitude of reduction of fibrinogen and plasminogen levels immediately after intracoronary streptokinase infusion in this study is similar to reported changes using intermittent i.v. infusion at higher doses, in which an initial induction dose of 600,000 IU is followed by additional short-course infusions at 24-hour intervals without a continuous maintenance infusion.16 ' 17 In addition, fibrinogen levels of 43% and plasminogen levels of 44% of baseline 24 hours after intracoronary infusion are in agreement with the intermittent i.v. infusion studies, which show fibrinogen levels of 50% and plasminogen levels of 45% 24 hours after an induction dose of 600,000 IU of streptokinase. 16 In our study, fibrinogen levels returned to normal at 30 hours and plasminogen levels at 48 hours.
Alterations of activated PTT occurred in all patients after streptokinase infusion and were probably due primarily to the effects of heparin given during the procedure. In patients without systemic fibrinolytic effect, PTT was only modestly prolonged, an effect that appeared to be predominantly the result of heparin. The marked prolongation of PTT in patients with major fibrinogen reduction may also reflect an active fibrinolytic state in addition to heparin effect. These marked alterations of PTT corrected relatively rapidly; PTT returned to a "therapeutic" range of 2-3 times control at 4.5 hours (range 0-12 hours) and to normal at 9 hours. After successful reperfusion by thrombolysis, antithrombotic therapy is continued with i.v. heparin anticoagulation to minimize the likelihood of recurrent thrombosis. The optimal timing for institution of continuous heparin infusion after thrombolysis has not been established, but periods of excess or insufficient anticoagulant effect should be avoided. Thus, optimal timing will depend upon whether streptokinase has resulted in a systemic fibrinolytic state causing major impairment of coagulation. Current practice suggests that heparin infusion should be initiated when the PTT is approximately twice control.'2-Current data indicate that PTT is at this level immediately after completion of streptokinase infusion in patients without systemic fibrinolytic effect and 4-12 hours (mean 5 hours) after infusion in patients with major systemic effects.
The prolongation of PT for the total group reflects the high percentage of patients with major fibrinogen reduction. The distribution and degree of alteration of PT after streptokinase infusion parallel the changes in activated PTT in subgroups of patients with and without systemic fibrinolytic effects: prolongation is minor in patients without significant fibrinogen reduction and marked in patients with systemic fibrinolytic activity. The minor changes appear to be primarily the result of heparin administered during the procedure; the major changes represent additional factors associated with a systemic fibrinolytic state, which include the lowered fibrinogen levels, interference of FDPs with the onestage thromboplastin time assay, and decreased factor V concentration due to proteolytic degradation by plasmin. 16 PT returns to normal more slowly than PTT: the group mean level is still above the normal range at 24 hours and values in individual patients return to normal at a mean of 20 hours after infusion. The delayed return of PT to normal may also partly reflect the addition of heparin infusion after streptokinase administration when the PTT had returned toward normal.
Elevated FDP levels were present in all patients after streptokinase administration and are consistent with some degree of fibrinolysis in patients with and without major fibrinogen reduction. In patients without fibrinogen reduction, FDPs returned to < 40 ,ug/ml within 12 hours. In patients with systemic effect, FDP remained > 40 ,ug/ml in all patients at 
